GSK touts topline win for PD-1 in head-to-head with Keytruda — while steering next big checkpoint drug into PhIII
GSK is claiming a win for what it calls the largest head-to-head trial pitting a PD-1 against Merck’s best-selling Keytruda in a type of lung …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
